9 Bladder Cancer Clinical Trials in Tucson, AZ (2026)

Q: How do I join a clinical trial in Tucson?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you.

Recruiting Bladder Cancer Studies in Tucson

NCT05987241Recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent th...

Tucson, AZPHASE2992 participantsNational Cancer Institute (NCI)

View Study Details

NCT03547973Recruiting

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC)....

Tucson, AZPHASE2827 participantsGilead Sciences

View Study Details

NCT06510374Recruiting

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)...

Tucson, AZPHASE3454 participantsFerring Pharmaceuticals

View Study Details

NCT07218380Recruiting

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugrati...

Tucson, AZPHASE3450 participantsEli Lilly and Company

View Study Details

NCT04752722Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phase...

Tucson, AZPHASE1350 participantsenGene, Inc.

View Study Details

NCT06567743Recruiting

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer....

Tucson, AZPHASE2325 participantsCG Oncology, Inc.

View Study Details

NCT06545955Recruiting

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3...

Tucson, AZPHASE3250 participantsFerring Pharmaceuticals

View Study Details

NCT05521698Recruiting

A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer

This phase I trial evaluates the effects of bicalutamide, compared to no study drug (NSD), on epidermal growth factor receptor (EGFR) protein expression in patients with non-muscle invasive bladder ca...

Tucson, AZPHASE180 participantsUniversity of Wisconsin, Madison

View Study Details

NCT05710848Recruiting

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients wit...

Tucson, AZPHASE175 participantsSURGE Therapeutics

View Study Details

About Bladder Cancer Clinical Trials in Tucson

Bladder cancer occurs in the tissues of the bladder and is one of the most common cancers. It has a high recurrence rate, requiring ongoing monitoring. Treatments include surgery, intravesical therapy, chemotherapy, and immunotherapy.

There are currently 9 bladder cancer clinical trials recruiting participants in Tucson, AZ. These studies are seeking a combined 3,803 participants. Research is being sponsored by National Cancer Institute (NCI), Gilead Sciences, Ferring Pharmaceuticals and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Bladder Cancer Clinical Trials in Tucson — FAQ

Are there bladder cancer clinical trials in Tucson?

Yes, there are 9 bladder cancer clinical trials currently recruiting in Tucson, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Tucson?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you about next steps.

Are clinical trials in Tucson free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tucson studies also compensate for your time and travel.

What bladder cancer treatments are being tested?

The 9 active trials in Tucson are testing new therapies including novel drugs, biologics, and treatment approaches for bladder cancer.

Data updated July 18, 2026 from ClinicalTrials.gov